|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19402-19407, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Free Radical Research Group, Department of Pathology,
Christchurch School of Medicine and Health Sciences, P. O. Box 4345, Christchurch, New Zealand
Received for publication, November 19, 2001, and in revised form, March 5, 2002
Diphenyleneiodonium (DPI) is a broad-spectrum
flavoprotein inhibitor commonly used to inhibit oxidant production by
the NADPH oxidase of phagocytic and nonphagocytic cells. A previous
study has shown that DPI can sensitize T24 bladder carcinoma cells to Fas-mediated apoptosis. We observed DPI to deplete intracellular reduced glutathione (GSH) in T24 cells and a range of other primary and
transformed cell types. The effect was immediate, with 50% loss of
intracellular GSH within 2 h of treatment with DPI. The glutathione was quantitatively recovered in the extracellular medium,
indicating that efflux was occurring. The loss of GSH was blocked with
bromosulfophthalein, an inhibitor of the canalicular GSH transporters.
We conclude that DPI induces a dramatic efflux of cellular GSH from T24
cells via a specific transport channel. This provides a
potential mechanism for its proapoptotic effect, and it also has
important implications for the regulation of glutathione homeostasis in cells.
Diphenyleneiodonium
(DPI)1 is a flavoprotein
inhibitor whose targets include the phagocyte NADPH oxidase, nitric
oxide synthase, xanthine oxidase, cytochrome P450 reductase, and
NADH:ubiquinone oxidoreductase (1-5). Electron transport through the
flavin moieties of these complexes causes reduction of DPI to its
radical form, followed by irreversible phenylation of either the flavin
or adjacent amino acid and heme groups (6, 7). Despite its nonspecific mode of action, DPI has been used extensively in recent years to block
NADPH oxidase activity in nonphagocytic cells, where the resultant
oxidants are proposed to play a role in cell signaling (8).
DPI has also been shown to sensitize T24 bladder carcinoma cells to
Fas-mediated apoptosis (9). Fas (CD95/Apo-1) is a member of the tumor
necrosis factor receptor superfamily and is widely expressed on normal
and transformed cells. Binding of the receptor with the Fas ligand or
an agonistic antibody triggers activation of the caspase cascade and
the induction of apoptosis (reviewed in Refs. 10 and 11). Resistance to
Fas-mediated apoptosis has been observed during normal cell development
and also in many types of tumor cells (12-18). Naïve T cells
are resistant to Fas ligand but become sensitive several days after
antigen activation (12). In tumor cells, down-regulation of signaling
through Fas has been implicated in tumorigenesis by promoting cell
survival and enabling evasion of cytotoxic T cells and in resistance to chemotherapeutic treatment (17, 19, 20).
Potential mechanisms of resistance explored thus far include decreased
receptor levels, increased expression of decoy receptors, failure to
form a functional signaling complex upon receptor oligomerization, inactive caspase mimics, and modulation of cell death by the
antiapoptotic proteins of the Bcl-2 family (12, 21-25). The ability of
DPI to sensitize cells to Fas-mediated apoptosis argues for some form of redox regulation. The observations of persistent oxidative stress in
tumor cells (26-28), combined with the sensitivity of caspases to
oxidative inactivation (29), raised the possibility of a DPI-sensitive
NADPH oxidase blocking apoptosis in resistant cells.
Reduced glutathione (GSH) is an important intracellular redox buffer
that can be oxidized to glutathione disulfide (GSSG) and protein mixed
disulfides and is in part responsible for the maintenance of protein
thiols in a reduced state (30, 31). Total intracellular glutathione
levels are under dynamic control. There is a continual efflux of GSH
from cells, followed by its extracellular degradation, uptake of
cysteine-containing precursors, and subsequent resynthesis (32).
Inhibition of GSH synthesis with buthionine sulfoximine depletes cells
of GSH over several hours (31).
We measured GSH and GSSG levels before and after treatment with DPI and
anti-Fas antibody to determine if the switch in sensitivity to Fas is
associated with changes in the glutathione redox couple in T24 cells.
To our surprise, we found that DPI triggered rapid GSH efflux, with
>50% loss over 2 h. This provides a potential mechanism for its
proapoptotic effect, and it also has important implications for the
regulation of glutathione homeostasis in cells.
Reagents--
Human anti-Fas IgM (clone CH-11) was purchased
from Upstate Biotechnology (Lake Placid, NY). The glutathione transport
inhibitor dibromosulfophthalein (DBSP) was purchased from
Société d'Études et de Recherches Biologiques
(Paris, France), and the caspase substrate
Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC) was purchased
from Peptide Institute, Inc. (Osaka, Japan). L-Methionine, dansyl chloride, DPI, and bromosulfophthalein (BSP) were from Sigma
Chemical Co. Cell culture materials were from Invitrogen New Zealand Ltd.
Cell Culture--
The T24 bladder carcinoma and Jurkat T
lymphocyte cell lines were obtained from American Type Culture
Collection (Manassas, VA). T24 cells were cultured in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin,
and 2 mM glutamine. Jurkat cells were maintained in RPMI
1640 medium containing 10% fetal bovine serum, 2 mM
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Human
umbilical vein endothelial cells were isolated from umbilical cords by
collagenase digestion (33) and cultured in Medium 199 supplemented with
20% fetal bovine serum, 100 µg/ml heparin, 30 µg/ml endothelial
cell growth factor, 25 units/ml penicillin, and 25 µg/ml streptomycin
on fibronectin-cultured plates (34). Fibroblasts were isolated from
human infant foreskins and cultured in minimum essential medium
containing 15% fetal bovine serum, 2 mM glutamine, 25 units/ml penicillin, and 25 µg/ml streptomycin as described
previously (35). All cell types were maintained at 37 °C in a
humidified atmosphere with 5% CO2.
Assessment of Membrane Integrity--
Plasma membrane integrity
was monitored using trypan blue staining. T24 cells were harvested from
culture dishes using a trypsin/EDTA solution, and cells were
resuspended in 0.2% trypan blue in phosphate-buffered saline and
analyzed by phase-contrast microscopy. Trypan blue-positive cells were
expressed as a percentage of the total number of counted cells.
Determination of Caspase Activity--
The measurement of
DEVD-AMC cleavage was modified from Nicholson et al. (36).
After treatment, cells were harvested with trypsin/EDTA and stored as
cell pellets at -80 °C. Immediately before assaying, the pellets
were thawed by the addition of 100 µl of buffer (100 mM
HEPES, 10% sucrose, 5 mM dithiothreitol (DTT), 10 Glutathione Determination--
Cellular GSH and GSSG levels were
measured by HPLC after derivatization with dansyl chloride as modified
from Martin and White (37). In brief, the supernatant was removed,
adherent cells were washed twice in phosphate-buffered saline, and
lysis buffer and iodoacetate were added. The cell samples were then
transferred to microcentrifuge tubes, the pH was corrected to pH 8-8.5
with lithium hydroxide, and the samples were incubated for 30 min. An
equal volume of 4 mg/ml dansyl chloride was added, and the extracts
were left in the dark for 60 min. Samples were then extracted in
chloroform and kept at 4 °C until HPLC analysis. Cell supernatants were derivatized as described above, except that a 2× concentration of
lysis buffer was used. To quantitatively measure GSH in the medium, the
cell supernatant was incubated with 500 µM DTT for 10 min
before the derivatization procedure. HPLC analysis was performed as
described previously (37).
DPI Sensitizes T24 Cells to Fas-mediated Apoptosis--
T24 cells
are one of the many cell lines known to be resistant to Fas-induced
apoptosis, despite surface expression of the receptor. As shown
previously (9), pretreatment of T24 cells with the flavoprotein
inhibitor DPI sensitized these cells to anti-Fas antibody (Fig.
1). Whereas the antibody or DPI alone had
little effect on the cells, characteristic apoptotic changes were
detectable within 6 h of a combination treatment. Cells were detaching from the plate, and extensive membrane blebbing was evident.
Caspase-3-like activity was increased 6-fold above control levels,
indicative of apoptosis (Fig. 1). By 24 h, >60% of these cells
were unable to exclude trypan blue (Fig. 1). DPI was equally effective
at causing cell death when added concurrently or 2 h after the
addition of anti-Fas antibody and also when it was present for 1 h
and then washed away before antibody addition (Fig. 1).
Effect of DPI on Intracellular GSH Levels--
To determine
whether DPI affected the redox balance of the cells, we measured
intracellular GSH and GSSG levels using the dansyl chloride HPLC assay.
To our surprise, we observed a rapid depletion of intracellular GSH in
the DPI-treated T24 cells (Fig. 2). The
loss was apparent within 30 min of adding 10 µM DPI.
After 2 h of treatment, GSH levels had dropped to 47 ± 10%
(S.D.; n = 9) of the control value, and after 4 h
only 29 ± 6% (S.D.; n = 5) of the GSH remained
in the cells (Fig. 3). Concurrent with the loss in cellular GSH, GSSG levels also dropped after incubation with DPI (Fig. 2, inset). Two h of treatment decreased T24
GSSG levels to 42 ± 12% (S.D.; n = 11) of
control, and 4 h of treatment with DPI decreased T24 GSSG levels
to 27 ± 12% (S.D.; n = 5). Whereas the direct
GSSG/GSH ratio remained constant, GSH levels are squared when
calculating the glutathione redox couple; therefore, we would predict a
more oxidizing intracellular environment. Determination of the absolute
reduction potential is dependent on the cell volume, but by
substituting the percentage losses in GSH and GSSG into the Nernst
equation (38), we calculated that DPI would cause a loss in
reduction potential of 9 mV at 2 h and 16 mV at 4 h.2
The anti-Fas antibody itself had a minimal effect on the GSH levels
(Fig. 3). When DPI was present for 1 h and then washed away, and
the cells were incubated for an additional hour in fresh media, GSH
levels were almost identical to those in cells that had been exposed to
DPI for the entire 2-h period (Fig. 3), indicating that GSH continued
to decrease after DPI removal. This correlates with the ability of DPI
pretreatment and removal to sensitize the cells to apoptosis (Fig. 1).
Treatment with increasing concentrations of DPI caused a
dose-dependent loss in cellular GSH, giving an IC50 of ~3 µM (Fig.
4). This compares with the 0.5 µM DPI observed for inhibition of superoxide production
by the neutrophil NADPH oxidase (39).
To investigate whether the DPI-induced GSH loss is specific to T24
cells, we measured GSH levels in Jurkat T lymphocytes and in primary
cultures of endothelial cells and fibroblasts after exposure to DPI.
All cell types suffered a progressive loss in intracellular GSH after
DPI treatment, with untreated cells either maintaining or increasing
their GSH levels over the 4-h period (Fig.
5). Thus, DPI induces a rapid depletion
of the glutathione pool in both primary and transformed cells,
suggesting a common target in these cell types.
Mechanism of GSH Loss in DPI-treated Cells--
We collected the
extracellular medium of DPI-treated T24 cells to determine whether
glutathione had been exported from the cells. A marked increase in the
area of a new peak with a retention time of ~7 min was observed (Fig.
6A). Due to a large excess of cystine in the medium, any GSH present extracellularly is likely to
react via thiol-disulfide exchange to form a GSH-cysteine mixed disulfide (40). To confirm that the unknown peak was the mixed disulfide, the products of the reaction between GSH and cystine were
also analyzed by HPLC. The major peak of this reaction eluted at the
same time as the unknown peak, and when the extracellular medium was
incubated with DTT before the derivatization procedure, the disulfide
peak disappeared, and GSH was detected (data not shown). Quantification
of extracellular levels after reduction with DTT showed that almost all
of the GSH lost from the DPI-treated cells was recovered in the
supernatant (Fig. 7).
It is possible that GSSG could be exported from the cells and react
with any trace cysteine present to give the mixed disulfide. Addition
of GSSG to DMEM produced some of the mixed disulfide, but a significant
amount of the GSSG remained after 3 h (Fig. 6B). The
absence of GSSG in the extracellular medium of DPI-treated cells (Fig.
6A) argues against the export of the oxidized species. The
experiments were also repeated in cystine-free media to prevent conversion to the mixed disulfide, therefore trapping the exported glutathione in its original form. After 3 h of treatment with DPI,
both GSH and GSSG were detected in the extracellular medium (Fig.
6C). However, the majority of the GSSG is likely to have come from oxidation of exported GSH because the addition of GSH to
cystine-free medium resulted in a substantial conversion to GSSG over a
similar incubation period (Fig. 6C). Therefore, although we
cannot exclude some of the glutathione being exported from the cells as
GSSG, the principal exported species appears to be GSH.
Because cells export and recycle GSH, extracellular accumulation could
occur as a result of impaired uptake and resynthesis rather than
increased efflux. To differentiate between these possibilities, we
measured both intracellular and extracellular GSH in the presence of
various inhibitors of GSH metabolism and compared their effects with
that of DPI. Buthionine sulfoximine, an inhibitor of
GSH transport has been studied almost exclusively in hepatocytes, with
GSH carrier systems described in both the sinusoidal and the
canalicular membranes, mediating release of GSH into the blood and the
bile, respectively (41-44). There is some evidence that these same
transporters exist in the plasma membrane of other mammalian cells (45,
46). When T24 cells were incubated with DPI and
L-methionine, an inhibitor of the low affinity sinusoidal GSH transporter (47, 48), the extent of intracellular GSH loss was the
same as that with DPI alone, suggesting that this carrier was not
responsible for the observed efflux (Fig.
8). BSP prevents GSH efflux from the
canalicular membrane of hepatocytes, inhibiting both the high and low
affinity transport components (42, 49). Addition of BSP alone to T24
cells resulted in some loss of intracellular GSH, probably because BSP
is a substrate for the glutathione S-transferases (50). When
cells were treated with BSP together with DPI, a
concentration-dependent reduction in the DPI-induced GSH
loss was observed (Fig. 8). Notably, 1 mM BSP prevented the
DPI-induced GSH loss completely, maintaining intracellular GSH at the
same levels as BSP alone. An analogue, DBSP, also
dose-dependently reduced the DPI-mediated GSH loss, with
complete inhibition occurring at 4 mM. However, it also
lowered T24 GSH levels (Fig. 8). These results strongly suggest that a BSP- and DBSP-sensitive carrier, probably one of the canalicular-like transporters, is mediating the DPI-induced efflux of GSH out of T24
cells. Because BSP and DBSP lower intracellular GSH levels themselves,
and they also enhance Fas-mediated apoptosis (data not shown), we were
unable to use them to test whether DPI still sensitizes T24 cells to
apoptosis when GSH efflux is prevented.
We have discovered that the flavoprotein inhibitor DPI causes a
rapid loss of intracellular GSH from cultured cells, with the missing
GSH recovered outside of the viable cell. This phenomenon was not cell
type-specific because it was observed in all the primary and
transformed cell types tested. The turnover of cellular glutathione is
well characterized, and GSH efflux is an integral component of this
pathway (Fig. 9) (32). Our results
indicate that the rate of GSH efflux is susceptible to modulation.
Indeed, efflux can be increased to such an extent that it outpaces the capacity of the cell for resynthesis and leads to severe depletion of
intracellular GSH within a few hours.
The increased GSH efflux was prevented by inhibitors of the canalicular
GSH transporters, indicating a specific efflux mechanism. GSH
transporters involved in extrusion of the tripeptide are poorly characterized and remain difficult to clone, and there is a general reliance on inhibitor studies to distinguish their activity (43, 44).
The concentration at which BSP inhibited efflux favors the low affinity
canalicular transport component as being the transporter responsible
for DPI-induced GSH loss. Higher concentrations are required to inhibit
it compared with the high affinity form (42), although it is not even
definitive whether the two are different proteins.
We do not know how DPI is triggering GSH efflux. A DPI-sensitive
flavoprotein may directly regulate the activity of a GSH transporter or
associated regulatory proteins. Alternatively, a cell might respond to
general metabolic changes upon treatment with DPI, such as an
accumulation of NAD(P)H, by increasing the rate of GSH efflux. We are
able to exclude two alternate mechanisms. Firstly, increased amounts of
DPI did not further increase the rate of GSH loss from the cells,
indicating that a direct conjugation reaction was not responsible for
GSH loss. Also, DPI could have acted by inhibiting glutathione
reductase, leading to the formation of GSSG and its export. We could
not detect evidence of significant GSSG formation inside or outside of
the cells, and the glutathione reductase inhibitor
bis-chloroethyl-nitrosourea had no effect on GSH levels (data not shown).
The ability of DPI to lower intracellular GSH levels provides a
feasible but as yet unproven mechanism for its ability to sensitize T24
cells to Fas-mediated apoptosis. A depletion of intracellular GSH has
been described in a number of different apoptotic systems (51-53),
with several studies showing that GSH loss in cells undergoing
apoptosis is the result of accelerated efflux rather than depletion by
oxidation (54, 55). In Jurkat cells treated with anti-Fas antibody, GSH
efflux occurred via a specific membrane channel, the low affinity
canalicular-like transporter, and the efflux was a downstream event
dependent on caspase activation (54). In contrast, others have shown
that U937 cells and HepG2 cells induced to undergo apoptosis with
puromycin efflux intracellular GSH, that the extrusion precedes other
apoptotic changes, and that maintenance of GSH was able to delay
apoptosis (55). The results are not necessarily in direct conflict. It may be that efflux of GSH is a common process in apoptotic cells but
that in some cell types, the loss of GSH is required early to allow
successful induction of the apoptotic program. It is also of interest
that the antiapoptotic protein Bcl-2 is linked to changes in GSH
metabolism in cells, in particular, a shift in the cellular redox state
toward a more reduced environment (56), increased intracellular GSH,
altered compartmentalization, and even modulation of GSH efflux
pathways (57-60).
In our model, the time course of GSH efflux is consistent with
sensitization, as is the ability to remove the DPI before activation of
the Fas pathway and still see GSH efflux and sensitization. At this
point, however, GSH efflux is associated with rather than responsible
for the sensitization of T24 cells to Fas-mediated apoptosis. A crucial
test of this hypothesis is to prevent GSH efflux and see if DPI still
sensitizes the cells to apoptosis. Unfortunately, the transport
inhibitors also depleted intracellular GSH, and they enhanced
Fas-mediated apoptosis themselves. It will be important to identify the
target of DPI and elucidate the pathways involved in controlling GSH
efflux, so that more selective compounds and/or molecular approaches
can be used to determine the role of DPI in sensitizing the tumor cells
to apoptosis.
We thank Prof. Christine Winterbourn for
valuable input and critical reading of the manuscript.
*
This work was supported in part by an Otago University
Research Grant and by the Cancer Society of New Zealand.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a grant from the Marsden Fund of the Royal Society of
New Zealand.
Published, JBC Papers in Press, March 19, 2002, DOI 10.1074/jbc.M111053200
2
At 2 h, GSH and GSSG levels were 47% and
42% of control, respectively. Substitution into the Nernst equation
( The abbreviations used are:
DPI, diphenyleneiodonium;
BSP, bromosulfophthalein;
DBSP, dibromosulfophthalein;
DTT, dithiothreitol;
GSH, reduced glutathione;
GSSG, glutathione disulfide;
DMEM, Dulbecco's modified Eagle's
medium;
DEVD, Ac-Asp-Glu-Val-Asp;
AMC, 7-amino-4-methylcoumarin;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
HPLC, high pressure liquid chromatography.
Diphenyleneiodonium Triggers the Efflux of Glutathione from
Cultured Cells*
and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
4% Nonidet P-40, and 0.1% CHAPS at pH
7.25) containing 50 µM DEVD-AMC. The rate of release of
fluorescent AMC was monitored at 37 °C (excitation, 370 nm;
emission, 445 nm), and the amount of AMC liberated was calculated from
a standard curve generated with the free compound.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (26K):
[in a new window]
Fig. 1.
DPI sensitizes T24 cells to Fas-mediated cell
death. T24 cells were transferred to fresh media and incubated
with DPI (10 µM) and anti-Fas antibody (0.25 µg/ml) as
described in the figure. Trypan blue-positive cells were measured after
24 h of anti-Fas treatment (
), and caspase activity was assayed
after 6 h of anti-Fas treatment (
). Results are the mean ± S.D. of three to four experiments.

View larger version (21K):
[in a new window]
Fig. 2.
DPI decreases T24 GSH levels without
increasing GSSG. T24 cells were transferred to fresh media for
1 h before the addition of 10 µM DPI. After 4 h, the cells were derivatized, and the samples were separated by HPLC.
The solid line represents control cells (1), and
the dashed line represents cells treated with DPI
(2). GSH and GSSG peaks are indicated. The inset
shows an enlargement of the GSSG peak for the two treatment
conditions.

View larger version (19K):
[in a new window]
Fig. 3.
Time course of GSH loss with DPI
treatment. T24 cells were transferred to fresh media for 1 h
and then incubated with DPI (10 µM) and anti-Fas antibody
(0.25 µg/ml) for up to 4 h as indicated (control,
; DPI,
;
Fas,
; DPI and Fas added concurrently,
) and 1 h with DPI,
followed by 1 h in fresh media (
). GSH levels are expressed in
nanomoles/well, with each 15-mm well containing ~140,000 cells and 40 µg of protein, and are duplicate determinations from one of three
representative experiments.

View larger version (13K):
[in a new window]
Fig. 4.
Concentration curve of GSH loss with DPI
treatment. T24 cells were transferred to fresh media for 1 h
and then incubated with DPI (0-20 µM) for 2 h. GSH
levels are expressed as nanomoles/well and are duplicate
determinations.

View larger version (20K):
[in a new window]
Fig. 5.
DPI decreases intracellular GSH in a variety
of cell types. Human umbilical vein endothelial cells (
,
),
fibroblasts (
,
), and Jurkat T lymphocytes (
,
) were
incubated in fresh media for 1 h, and then 10 µM DPI
was added or the cells were left untreated for up to 4 h. Cells
were derivatized with dansyl chloride and separated by HPLC. Untreated
cells, filled symbols; cells exposed to DPI, open
symbols. Results are expressed as a percentage of control and are
the mean ± range of a representative experiment performed in
duplicate. Human umbilical vein endothelial cells and fibroblasts
contained ~3.38 ± 0.01 and 1.39 ± 0.06 nmol GSH/well,
respectively, with 1 × 106 Jurkat T cells containing
2.89 ± 0.04 nmol GSH/well. This equates to 28, 16, and 3 fmol/cell, respectively.

View larger version (14K):
[in a new window]
Fig. 6.
Glutathione species present in the
extracellular medium of T24 cells. A, T24 cells were
transferred to fresh DMEM for 1 h, and then 10 µM
DPI was added (1), or the cells were left untreated
(2). After 3 h, the cell supernatant was derivatized
with dansyl chloride and separated by HPLC. Fresh DMEM is shown
in 3. B, GSSG was added to DMEM and incubated for
3 h at 37 °C (1). Fresh DMEM is shown in
2. C, T24 cells were transferred to fresh DMEM
for 1 h and washed in phosphate-buffered saline, and then
cystine-free medium was added, and the cells were treated with 10 µM DPI (1) or left untreated (2)
for 3 h. GSH was added to cystine-free medium and incubated for
3 h at 37 °C (3).

View larger version (26K):
[in a new window]
Fig. 7.
Intracellular and extracellular GSH levels in
T24 cells. Cells were incubated in fresh media for 1 h, and
then DPI (10 µM), acivicin (125 µM),
buthionine sulfoximine (25 µM), or cystine-free medium
was added, or the cells were left untreated. After 4 h, the media
were removed, reduced with 500 µM DTT for 10 min, and
both the intracellular fraction (
) and the extracellular medium
(
) were derivatized with dansyl chloride. Results are expressed as a
percentage of the total GSH in control cells and are the mean ± S.D. of three to five experiments.
-glutamylcysteine synthetase that catalyzes the rate-limiting step
of GSH synthesis, and acivicin, an inhibitor of the enzyme
-glutamyl
transpeptidase involved in recycling extracellular GSH, both decreased
T24 GSH levels by ~30% over a 4-h period (Fig. 7). This was
considerably slower than DPI, whereas adding both together lowered GSH
to a level approaching that of DPI. However, neither caused the
accumulation of extracellular GSH. Incubation of T24 cells in
cystine-free medium, which will impair both new synthesis and the
recycling pathways, induced a rapid drop in intracellular GSH similar
to that of DPI. However, there was again no corresponding increase in
GSH in the cell supernatant, indicating a different mode of action than
DPI (Fig. 7). Unlike DPI, incubation with buthionine sulfoximine,
acivicin, and cystine-free medium all resulted in a loss in the
total GSH levels (Fig. 7). We conclude that DPI decreases
intracellular GSH levels by enhancing the rate of GSH efflux rather
than by inhibiting precursor uptake or biosynthesis.

View larger version (34K):
[in a new window]
Fig. 8.
DPI-induced GSH loss is inhibited by BSP and
DBSP. T24 cells were incubated in fresh media for 1 h. The
GSH transporter inhibitors, L-methionine, BSP, and DBSP,
were added just before 10 µM DPI, and the cells were
incubated for an additional 2 h. After derivatization with dansyl
chloride, the cell lysates were separated by HPLC. Results are
presented as a percentage of the control value and are the mean ± S.D. of three to five experiments. The open bars show the
transport inhibitors alone, whereas the filled bars show
them in combination with DPI.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (16K):
[in a new window]
Fig. 9.
Pathway of GSH metabolism. The majority
of GSH in cultured cells is derived from cystine present in the culture
medium. Intracellular GSH is also effluxed from the cell, where it
reacts with cystine to form GSH-cysteine mixed disulfide. Exported GSH
may also react with
-glutamyl transpeptidase and cystine to form
-glutamyl-cystine, which is transported into the cell and reduced
intracellularly to form
-glutamyl cysteine and cysteine.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.: 64-3-364-0565;
Fax: 64-3-364-1083; E-mail: juliet.pullar@chmeds.ac.nz.
240
(61.5/2) × log (0.472/0.42)) generates
a loss in reduction potential of 9 mV. This calculation is independent
of the initial reduction potential but dependent on the cell volume
remaining constant.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Cross, A. R.,
and Jones, O. T. G.
(1986)
Biochem. J.
237,
111-116[Medline]
[Order article via Infotrieve]
2.
Doussiere, J.,
and Vignais, P. V.
(1992)
Eur. J. Biochem.
208,
61-71[Medline]
[Order article via Infotrieve]
3.
Stuehr, D. J.,
Fasehun, O. A.,
Kwon, N. S.,
Gross, S. S.,
Gonzalez, J. A.,
Levi, R.,
and Nathan, C. F.
(1991)
FASEB J.
5,
98-103[Abstract]
4.
Li, Y.,
and Trush, M. A.
(1998)
Biochem. Biophys. Res. Commun.
253,
295-299[CrossRef][Medline]
[Order article via Infotrieve]
5.
Ragan, C. I.,
and Bloxham, D. P.
(1977)
Biochem. J.
163,
605-615[Medline]
[Order article via Infotrieve]
6.
O'Donnell, V. B.,
Tew, D. G.,
Jones, O. T. G.,
and England, P. J.
(1993)
Biochem. J.
290,
41-49[Medline]
[Order article via Infotrieve]
7.
Doussiere, J.,
Gaillard, J.,
and Vignais, P. V.
(1999)
Biochemistry
38,
3694-3703[CrossRef][Medline]
[Order article via Infotrieve]
8.
Finkel, T.
(2000)
FEBS Lett.
476,
52-54[CrossRef][Medline]
[Order article via Infotrieve]
9.
Clement, M. V.,
and Stamenkovic, I.
(1996)
EMBO J.
15,
216-225[Medline]
[Order article via Infotrieve]
10.
Krammer, P. H.
(2000)
Nature
407,
789-795[CrossRef][Medline]
[Order article via Infotrieve]
11.
Siegel, R. M.,
Chan, F. K.,
Chun, H. J.,
and Lenardo, M. J.
(2000)
Nat. Immunol.
1,
469-474[CrossRef][Medline]
[Order article via Infotrieve]
12.
O'Flaherty, E.,
Wong, W. K.,
Pettit, S. J.,
Seymour, K.,
Ali, S.,
and Kirby, J. A.
(2000)
Immunology
100,
289-299[CrossRef][Medline]
[Order article via Infotrieve]
13.
Jenkins, M.,
Keir, M.,
and McCune, J. M.
(1999)
J. Immunol.
163,
1195-1204 14.
Willems, F.,
Amraoui, Z.,
Vanderheyde, N.,
Verhasselt, V.,
Aksoy, E.,
Scaffidi, C.,
Peter, M. E.,
Krammer, P. H.,
and Goldman, M.
(2000)
Blood
95,
3478-3482 15.
Mori, S.,
Murakami-Mori, K.,
Jewett, A.,
Nakamura, S.,
and Bonavida, B.
(1996)
Cancer Res.
56,
1874-1879 16.
Natoli, G.,
Ianni, A.,
Costanzo, A., De,
Petrillo, G.,
Ilari, I.,
Chirillo, P.,
Balsano, C.,
and Levrero, M.
(1995)
Oncogene
11,
1157-1164[Medline]
[Order article via Infotrieve]
17.
Owen-Schaub, L. B.,
Radinsky, R.,
Kruzel, E.,
Berry, K.,
and Yonehara, S.
(1994)
Cancer Res.
54,
1580-1586 18.
Shima, Y.,
Nishimoto, N.,
Ogata, A.,
Fujii, Y.,
Yoshizaki, K.,
and Kishimoto, T.
(1995)
Blood
85,
757-764 19.
Micheau, O.,
Solary, E.,
Hammann, A.,
and Dimanche-Boitrel, M. T.
(1999)
J. Biol. Chem.
274,
7987-7992 20.
Krammer, P. H.
(1997)
Cell Death Differ.
4,
362-364[Medline]
[Order article via Infotrieve]
21.
Adams, J. M.,
and Cory, S.
(1998)
Science
281,
1322-1326 22.
Midis, G. P.,
Shen, Y.,
and L., B.
(1996)
Cancer Res.
56,
3870-3874 23.
Scaffidi, C.,
Schmitz, I.,
Krammer, P. H.,
and Peter, M. E.
(1999)
J. Biol. Chem.
274,
1541-1548 24.
Pitti, R. M.,
Marsters, S. A.,
Lawrence, D. A.,
Roy, M.,
Kischkel, F. C.,
Dowd, P.,
Huang, A.,
Donahue, C. J.,
Sherwood, S. W.,
Baldwin, D. T.,
Godowski, P. J.,
Wood, W. I.,
Gurney, A. L.,
Hillan, K. J.,
Cohen, R. L.,
Goddard, A. D.,
Botstein, D.,
and Ashkenazi, A.
(1998)
Nature
396,
699-703[CrossRef][Medline]
[Order article via Infotrieve]
25.
Poulaki, V.,
Mitsiades, N.,
Romero, M. E.,
and Tsokos, M.
(2001)
Cancer Res.
61,
4864-4872 26.
Toyokuni, S.,
Okamoto, K.,
Yodoi, J.,
and Hiai, H.
(1995)
FEBS Lett.
358,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
27.
Szatrowski, T. P.,
and Nathan, C. F.
(1991)
Cancer Res.
51,
794-798 28.
Cerutti, P. A.
(1985)
Science
227,
375-381 29.
Hampton, M. B.,
and Orrenius, S.
(1997)
FEBS Lett.
414,
552-556[CrossRef][Medline]
[Order article via Infotrieve]
30.
Lu, S. C.
(1999)
FASEB J.
13,
1169-1183 31.
Griffith, O. W.
(1999)
Free Radic. Biol. Med.
27,
922-935[CrossRef][Medline]
[Order article via Infotrieve]
32.
Meister, A.
(1994)
Cancer Res.
54,
1969s-1975s 33.
Jaffe, E.,
Nachman, R. L.,
Becker, C. G.,
and Minick, C. R.
(1973)
J. Clin. Invest.
52,
2745-2756[Medline]
[Order article via Infotrieve]
34.
Pullar, J. M.,
Winterbourn, C. C.,
and Vissers, M. C. M.
(1999)
Am. J. Physiol.
277,
H1505-H1512[Medline]
[Order article via Infotrieve]
35.
Vile, G. F.,
Rothwell, L. A.,
and Kettle, A. J.
(2000)
Arch. Biochem. Biophys.
377,
122-128[CrossRef][Medline]
[Order article via Infotrieve]
36.
Nicholson, D. W.,
Ali, A.,
Thornberry, N. A.,
Vaillancourt, J. P.,
Ding, C. K.,
Gallant, M.,
Gareau, Y.,
Griffin, P. R.,
Labelle, M.,
and Lazebnik, Y. A.
(1995)
Nature
376,
37-43[CrossRef][Medline]
[Order article via Infotrieve]
37.
Martin, J.,
and White, I. N. H.
(1991)
J. Chromatogr.
568,
219-225[Medline]
[Order article via Infotrieve]
38.
Schafer, F. Q.,
and Buettner, G. R.
(2001)
Free Radic. Biol. Med.
30,
1191-1212[CrossRef][Medline]
[Order article via Infotrieve]
39.
Hampton, M. B.,
and Winterbourn, C. C.
(1995)
Free Radic. Biol. Med.
18,
633-639[CrossRef][Medline]
[Order article via Infotrieve]
40.
Gilbert, H. F.
(1990)
Adv. Enzymol.
63,
69-172[CrossRef][Medline]
[Order article via Infotrieve]
41.
Fernandez-Checa, J. C.,
Takikawa, H.,
Horie, T.,
Ookhtens, M.,
and Kaplowitz, N.
(1992)
J. Biol. Chem.
267,
1667-1673 42.
Ballatori, N.,
and Dutczak, W. J.
(1994)
J. Biol. Chem.
269,
19731-19737 43.
Mittur, A. V.,
Kaplowitz, N.,
Kempner, E. S.,
and Ookhtens, M.
(1998)
Am. J. Physiol.
274,
G923-G930[Medline]
[Order article via Infotrieve]
44.
Mittur, A. V.,
Kaplowitz, N.,
Kempner, E. S.,
and Ookhtens, M.
(2000)
Biochim. Biophys. Acta
1464,
207-218[Medline]
[Order article via Infotrieve]
45.
Lu, S. C.,
Sun, W. M.,
Nagineni, C. N.,
Hooks, J. J.,
and Kannan, R.
(1995)
Investig. Ophthalmol. Vis. Sci.
36,
2523-2530 46.
Lu, S. C.,
Sun, W. M., Yi, J.,
Ookhtens, M.,
Sze, G.,
and Kaplowitz, N.
(1996)
J. Clin. Invest.
97,
1488-1496[Medline]
[Order article via Infotrieve]
47.
Aw, T. Y.,
Ookhtens, M.,
and Kaplowitz, N.
(1984)
J. Biol. Chem.
259,
9355-9358 48.
Aw, T. Y.,
Ookhtens, M.,
and Kaplowitz, N.
(1986)
Am. J. Physiol.
251,
G354-G361[Medline]
[Order article via Infotrieve]
49.
Ballatori, N.,
and Clarkson, T. W.
(1985)
Am. J. Physiol.
248,
G238-G245[Medline]
[Order article via Infotrieve]
50.
Habig, W. H.,
Pabst, M. J.,
and Jakoby, W. B.
(1974)
J. Biol. Chem.
249,
7130-7139 51.
Fernandez, A.,
Kiefer, J.,
Fosdick, L.,
and McConkey, D. J.
(1995)
J. Immunol.
155,
5133-5139[Abstract]
52.
Macho, A.,
Hirsch, T.,
Marzo, I.,
Marchetti, P.,
Dallaporta, B.,
Susin, S. A.,
Zamzami, N.,
and Kroemer, G.
(1997)
J. Immunol.
158,
4612-4619[Abstract]
53.
Ghibelli, L.,
Coppola, S.,
Rotilio, G.,
Lafavia, E.,
Maresca, V.,
and Ciriolo, M. R.
(1995)
Biochem. Biophys. Res. Commun.
216,
313-320[CrossRef][Medline]
[Order article via Infotrieve]
54.
van den Dobbelsteen, D. J.,
Nobel, C. S.,
Schlegel, J.,
Cotgreave, I. A.,
Orrenius, S.,
and Slater, A. F.
(1996)
J. Biol. Chem.
271,
15420-15427 55.
Ghibelli, L.,
Fanelli, C.,
Rotilio, G.,
Lafavia, E.,
Coppola, S.,
Colussi, C.,
Civitareale, P.,
and Ciriolo, M. R.
(1998)
FASEB J.
12,
479-486 56.
Ellerby, L. M.,
Ellerby, H. M.,
Park, S. M.,
Holleran, A. L.,
Murphy, A. N.,
Fiskum, G.,
Kane, D. J.,
Testa, M. P.,
Kayalar, C.,
and Bredesen, D. E.
(1996)
J. Neurochem.
67,
1259-1267[Medline]
[Order article via Infotrieve]
57.
Mirkovic, N.,
Voehringer, D. W.,
Story, M. D.,
McConkey, D. J.,
McDonnell, T. J.,
and Meyn, R. E.
(1997)
Oncogene
15,
1461-1470[CrossRef][Medline]
[Order article via Infotrieve]
58.
Meredith, M. J.,
Cusick, C. L.,
Soltaninassab, S.,
Sekhar, K. S., Lu, S.,
and Freeman, M. L.
(1998)
Biochem. Biophys. Res. Commun.
248,
458-463[CrossRef][Medline]
[Order article via Infotrieve]
59.
Voehringer, D. W.,
McConkey, D. J.,
McDonnell, T. J.,
Brisbay, S.,
and Meyn, R. E.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2956-2960 60.
Voehringer, D. W.
(1999)
Free Radic. Biol. Med.
27,
945-950[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. P. Wilkie, M. C. M. Vissers, M. Dragunow, and M. B. Hampton A Functional NADPH Oxidase Prevents Caspase Involvement in the Clearance of Phagocytic Neutrophils Infect. Immun., July 1, 2007; 75(7): 3256 - 3263. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Finkelstein, J. Ruben, C. W. Koot, M. Hristova, and A. van der Vliet Regulation of constitutive neutrophil apoptosis by the {alpha},{beta}-unsaturated aldehydes acrolein and 4-hydroxynonenal Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L1019 - L1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Lee, Y. G. Choi, J. Y. Baik, S. Y. Han, D.-w. Jeong, Y. S. Bae, N. Kim, and S. Y. Lee A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation Blood, August 1, 2005; 106(3): 852 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Perrone, C. M. Grant, and I. W. Dawes Genetic and Environmental Factors Influencing Glutathione Homeostasis in Saccharomyces cerevisiae Mol. Biol. Cell, January 1, 2005; 16(1): 218 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Riganti, E. Gazzano, M. Polimeni, C. Costamagna, A. Bosia, and D. Ghigo Diphenyleneiodonium Inhibits the Cell Redox Metabolism and Induces Oxidative Stress J. Biol. Chem., November 12, 2004; 279(46): 47726 - 47731. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Trompier, X.-B. Chang, R. Barattin, A. d. M. d'Hardemare, A. Di Pietro, and H. Baubichon-Cortay Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 Cancer Res., July 15, 2004; 64(14): 4950 - 4956. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pullar, S. J. Thomson, M. J. King, C. I. Turnbull, R. G. Midwinter, and M. B. Hampton The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis Carcinogenesis, May 1, 2004; 25(5): 765 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. He, J.-L. Huang, D. C. Ramirez, and C. F. Chignell Role of Reduced Glutathione Efflux in Apoptosis of Immortalized Human Keratinocytes Induced by UVA J. Biol. Chem., February 28, 2003; 278(10): 8058 - 8064. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Parinandi, M. A. Kleinberg, P. V. Usatyuk, R. J. Cummings, A. Pennathur, A. J. Cardounel, J. L. Zweier, J. G. N. Garcia, and V. Natarajan Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L26 - L38. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||